Publications

Blood-based biomarkers and 20-year risk of clinically diagnosed Alzheimer’s disease

Littlejohns T. et al, (2026)

Statistics in Medicine - What's in an Estimand?

Troxel AB. et al, (2026), The New England journal of medicine, 394, 6 - 9

Public Health.

Gao Y. et al, (2025), Alzheimer's & dementia : the journal of the Alzheimer's Association, 21 Suppl 6

Biomarkers.

Gao Y. et al, (2025), Alzheimer's & dementia : the journal of the Alzheimer's Association, 21 Suppl 2

Our Future Health: a unique global resource for discovery and translational research.

Cook MB. et al, (2025), Nature medicine, 31, 728 - 730

Associations between disease-specific polygenic risk scores and disease-specific causes of death in the UK Biobank cohort

Liu W. et al, (2025)

"Target Trial Emulation" for Observational Studies - Potential and Pitfalls.

Hubbard RA. et al, (2024), The New England journal of medicine, 391, 1975 - 1977

Publisher Correction: Understanding the genetic complexity of puberty timing across the allele frequency spectrum.

Kentistou KA. et al, (2024), Nature genetics, 56, 1763 - 1764

Understanding the genetic complexity of puberty timing across the allele frequency spectrum.

Kentistou KA. et al, (2024), Nature genetics, 56, 1397 - 1411

Table 1 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Collister JA. et al, (2024)

Supplementary Table S8 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Collister JA. et al, (2024)

Supplementary Table S7 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Collister JA. et al, (2024)

Table 2 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Collister JA. et al, (2024)

Table 3 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Collister JA. et al, (2024)

Supplementary Table S9 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Collister JA. et al, (2024)

Supplementary Table S6 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Collister JA. et al, (2024)

Supplementary Table S9 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Collister JA. et al, (2024)

Supplementary Table S8 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Collister JA. et al, (2024)

Table 3 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Collister JA. et al, (2024)

Table 2 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Collister JA. et al, (2024)

Cookies on this website

Search results (319)

Blood-based biomarkers and 20-year risk of clinically diagnosed Alzheimer’s disease

Statistics in Medicine - What's in an Estimand?

Public Health.

Biomarkers.

Our Future Health: a unique global resource for discovery and translational research.

Associations between disease-specific polygenic risk scores and disease-specific causes of death in the UK Biobank cohort

"Target Trial Emulation" for Observational Studies - Potential and Pitfalls.

Publisher Correction: Understanding the genetic complexity of puberty timing across the allele frequency spectrum.

Understanding the genetic complexity of puberty timing across the allele frequency spectrum.

Table 1 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Supplementary Table S8 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Supplementary Table S7 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Table 2 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Table 3 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Supplementary Table S9 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Supplementary Table S6 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Supplementary Table S9 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Supplementary Table S8 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Table 3 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank

Table 2 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank